跳至主要内容
临床试验/EUCTR2013-003940-21-NL
EUCTR2013-003940-21-NL进行中(未招募)不适用

Systemic antibiotic therapy (amoxicillin plus metronidazole) as an adjunct to surgical treatment of peri-implantitis; a single blind randomized controlled study - Systemic amoxicillin plus metronidazole in surgical peri-implantitis treatment

niversity Medical Center Groningen0 个研究点开始时间: 2013年10月18日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1) The patient is = 18 years of age;
  • 2) The patient has at least one endosseous implant in the oral cavity with clinical and radiographical signs of peri-implantitis. Peri-implantitis is defined as a loss of marginal bone = 2 mm as compared to the shoulder of the implant (the level at which the bone is normally located immediately after implant placement), in combination with bleeding and/or suppuration on probing and a peri-implant probing depth = 5 mm;
  • 3) The implants have been in function for at least two years;
  • 4) The patient is capable of understanding and giving informed consent.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 40
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 20

排除标准

  • 1) Medical and general contraindications for the surgical procedures;
  • 2) A history of local radiotherapy to the head and neck region;
  • 3) Pregnancy and lactation;
  • 4) Uncontrolled diabetes (HbA1c < 7% or < 53 mmol/mol)
  • 5) Mononucleosis infectiosa
  • 6) Organic neurological disorders
  • 7) Use of antibiotics during the last 3 months;
  • 8) Known allergy to amoxicillin, metronidazole or chlorhexidine;
  • 9) Long-term use of anti-inflammatory drugs;
  • 10) Full edentulism (no remaining teeth, only implants)
  • 11) Active periodontal disease at remaining dentition (PPD=6mm, bleeding=20%) and/or insufficient oral hygiene (plaque=20%)
  • 12) Implants placed in areas augmented with autogenous bone from the crista iliac region;
  • 13) Implants placed in skin grafted areas;
  • 14) Implants with bone loss exceeding 2/3 of the length of the implant or implants with bone loss beyond the transverse openings in hollow implants;
  • 15) Implant mobility;
  • 16) Implants at which no position can be identified where proper probing measurements can be performed;
  • 17) Previous surgical treatment of the peri-implantitis lesions;

研究者

相似试验